Skip to main content
Delfa

← All assets

Solanezumab

12 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

12

Ongoing

1

Recruiting

0

Completed

7

Sites

592

Countries

21

Endpoints

255

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 255 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
1
Phase 2
3
Phase 2/3
2
Phase 3
6

Trials by status

Active, not recruiting
1
Completed
7
Terminated
4

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
90
Amyloid biomarkers
41
Function / daily living
20
Safety / tolerability / PK
18
Behavior / neuropsychiatric
16
Memory
15
Neuroimaging
14
Other (unclassified)
11
Fluid / digital biomarkers
10
Caregiver / quality of life
10
Tau biomarkers
6
Neurodegeneration biomarkers
4

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 85 of 255 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Mini-Mental State Examination (MMSE)Cognition

23

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

14

ADAS-CogCognition

11

ADCS-Activities of Daily Living (ADCS-ADL)Function

10

Neuropsychiatric Inventory (NPI)Behavior

8

Neurofilament light (NfL)Neurodeg.

4

ADAS-CogMemory

4

ADAS-CogOther

3

Neuropsychiatric Inventory (NPI)Cognition

2

Phosphorylated tau 181 (p-tau181)Tau

2

Montreal Cognitive Assessment (MoCA)Cognition

2

Phosphorylated tau 181 (p-tau181)Amyloid

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

12 of 12

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
EXPEDITION 3Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo

Solanezumab

Alzheimer’s disease

Alzheimer's diseasePh 3Terminated198Oct 20163results
ExpeditionPROA Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

Solanezumab

Alzheimer’s disease

prodromal ADPh 3Terminated193May 2017-results
EXPEDITION EXTContinued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

Solanezumab

Alzheimer’s disease

Alzheimer's diseasePh 3Terminated147Jul 2014-results
EXPEDITION2Effect of LY2062430 on the Progression of Alzheimer's Disease

Solanezumab

Alzheimer’s disease

mild-to-moderate ADPh 3Completed95Jun 20127
EXPEDITIONEffect of LY2062430 on the Progression of Alzheimer's Disease

Solanezumab

Alzheimer’s disease

mild-to-moderate ADPh 3Completed85Apr 20127
A4Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss

Solanezumab

Alzheimer’s disease

Amyloid biomarker required (PET)Ph 3Completed68Dec 202212results
DIAN-TUDominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

E2814, Gantenerumab, Lecanemab, Solanezumab

Alzheimer’s disease

Study partner/caregiver requiredPh 2/3Active, not recruiting38Apr 202815
DIAN-TUDominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.

Gantenerumab, Solanezumab

Alzheimer’s disease

Study partner/caregiver requiredPh 2/3Completed25Nov 201913results
NCT00749216Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease

Solanezumab

Alzheimer’s disease

mild-to-moderate ADPh 2Completed6Jul 2009-
NCT00329082Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers

Solanezumab

Alzheimer’s disease

mild-to-moderate ADPh 2Completed6May 2008-
NCT02614131A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

LY2599666, Solanezumab

Alzheimer’s disease, MCI / preclinical Alzheimer’s

mild-to-moderate ADPh 1Terminated5Dec 2016-results
NCT01148498A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's

Solanezumab

Alzheimer’s disease

Alzheimer's diseasePh 2Completed1Aug 2012-

Showing 1-12 of 12 trials